Innovative and novel financing and reimbursement strategies may be needed to support sustainable patient access to these new treatments. During this session, managed care and provider strategies for addressing gene therapy will be explored.

The potential for gene therapy to transform the treatment of a wide variety of health conditions has important implications for many stakeholders. During this panel discussion, participants will have the opportunity to hone in on pressing issues raised throughout the conference and discuss these issues with a panel of experts with varying backgrounds, including both clinical and managed care perspectives.

Departure from traditional dosage-based models makes it difficult for therapy developers, payers, patients, and investors to plan for a new therapy’s rollout and breadth of patient access. This session will explore the early lessons from current value-based agreements to explain the payers’ expectations for future models of reimbursing treatments based on outcomes versus delivery.

The pharmaceutical landscape is littered with the market-access failures of recent biotech launches – the reason investors now often “sell on the launch” — innovative science and a biotechs’ vision of “unmet medical need” are often irrelevant or meaningless to payers. Even the earliest target product profile needs to reflect “unmet need” from the payer’s point of view – using an objective, broad and forward-looking understanding of competition — and create a medical and economic roadmap for minimizing payer restrictions.

The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.

The FH Global Summit is the only conference dedicated to solving global challenges in the care and treatment of familial hypercholesterolemia (FH) through a multi-stakeholder and interdisciplinary approach. An invitation-only event, the summit features a stellar lineup of speakers and panelists who are experts in FH, genomics, precision medicine, alongside leading healthcare practitioners, individuals with FH and industry.